Egyptian healthtech startup Reme-D has raised $1.45 million in a Pre-Sequence A funding spherical led by Anara Influence Capital to develop manufacturing of its molecular diagnostic exams and develop its presence throughout Africa and different underserved markets.
The spherical included participation from the World Innovation Fund, Africa Well being Ventures and different buyers. The funding follows a $500,000 funding from the World Innovation Fund in April and can assist larger manufacturing capability, regional growth and the event of recent diagnostic merchandise.
Based in 2023 by Salma Tammam, Reme-D develops molecular diagnostic exams for illnesses together with tuberculosis, HIV, hepatitis and human papillomavirus (HPV). Its merchandise are designed to stay steady at larger temperatures, lowering the necessity for cold-chain storage and making them simpler to distribute in distant areas with restricted healthcare infrastructure.
Since launching, the Cairo-based firm has developed and commercialized 30 diagnostic merchandise and equipped greater than 550,000 exams throughout Egypt, Kenya and Sudan. Reme-D additionally just lately outfitted a solar-powered cellular laboratory commissioned by the World Well being Group’s Egypt workplace to assist the nation’s monitoring of vector-borne illnesses. The corporate plans to maneuver into a brand new 1,500-square-meter manufacturing facility, rising manufacturing capability tenfold whereas increasing into diagnostics for genetic illnesses and most cancers.
Sustain with the newest headlines on WhatsApp | LinkedIn
Key Takeaways
Reme-D’s newest funding highlights rising investor curiosity in African corporations constructing native healthcare manufacturing fairly than counting on imported medical merchandise. Africa imports most of its diagnostic tools and laboratory consumables, leaving many international locations uncovered to provide chain disruptions and excessive prices. By producing molecular diagnostic exams domestically, Reme-D goals to shorten supply instances, cut back prices and enhance entry to superior testing for illnesses that stay main public well being challenges throughout the continent. The corporate’s deal with temperature-resilient diagnostics additionally addresses certainly one of Africa’s greatest healthcare infrastructure constraints, the place dependable refrigeration is commonly unavailable outdoors main cities.
The growth into genetic illness and most cancers diagnostics displays rising demand for extra superior testing as African healthcare techniques strengthen screening and early detection applications. For buyers, the corporate represents a broader pattern towards backing well being know-how companies that mix native manufacturing, scientific analysis and regional distribution. If Reme-D efficiently scales manufacturing and expands throughout extra African markets, it may assist cut back dependence on imported diagnostics whereas supporting quicker illness detection and therapy throughout private and non-private healthcare techniques.
Join free AllAfrica Newsletters
Get the newest in African information delivered straight to your inbox
